The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 1, 1997, Pages 25-33

  Devine, Steven M ^a   Geller, Robert B ^b   Lin, Lillian B ^b   Dix, Suzanne P ^b   Holland, H Kent ^b   Maurer, David ^b   O'Toole, Kathleen ^b   Keller, James ^b   Connaghan, Daniel G ^b   Heffner, Leonard T ^b   Hillyer, Christopher D ^b   Rodey, Glenn E ^b   Winton, Elliott F ^b   Maher, Rochelle M ^b   Fitzsimmons, William E ^b   Wingard, John R ^b  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; TACROLIMUS;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; KIDNEY DISEASE; LIFE TABLE; LIVER DISEASE; MALE; MIDDLE AGED; MORTALITY; PILOT STUDY; SAFETY; SURVIVAL; TREATMENT OUTCOME; VIROLOGY;

ADULT; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; HUMANS; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY DISEASES; LIFE TABLES; LIVER DISEASES; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; SAFETY; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0031113473     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Thomas ED: Karnofsky memorial lecture: Marrow transplantation for malignant diseases. J Clin Oncol 1:517, 1983.
2. McGlave PB: The biology and therapy of chronic myelogenous leukemia, in Champlin R (ed): Bone Marrow Transplantation. Boston, MA, Martin Nijhoff, 1990, p 235.
3. Beatty PG, Clift RA, Mickelson EM, Nisperos B, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, Thomas ED, Hansen JA: Marrow transplantation from related donors other than HLA identical siblings. N Engl J Med 313:765, 1985.
4. Hows JM, Yin JL, Marsh J, Swirsky D, Jones L, Apperley JF, James DCO, Smithers S, Batchelor JR, Goldman JM, Gordon-Smith EC: Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 68:1322, 1986.
5. Howard MR, Hows JM, Gore SM, Barrett J, Brenner MK, Goldman JM, Gordon-Smith EC, Poynton C, Prentice HG, Whittaker JA, Bradley BA: Unrelated donor marrow transplantation between 1977 and 1987 at four centers in the United Kingdom. Transplantation 49:547, 1990.
6. Gingrich RD, Ginder GD, Goeken NE, Howe CWS, Wen BC, Hussey DH, Fyfe MA: Allogeneic marrow grafting with partially mismatched, unrelated marrow donors. Blood 71:1375, 1988.
7. Mackinnon S, Hows JM, Goldman JM, Arthur CK, Hughes T, Apperley JF, Jones L, Batchelor JR, Brookes P, Catovsky D, Galton DAG, Bidwell J, Bradley B, Cleaver S, Hale G, Waldmann H: Bone marrow transplantation for chronic myeloid leukemia: The use of histocompatible unrelated volunteer donors. Exp Hematol 18:421, 1990.
8. Gajewski JL, Ho WG, Feig SA, Hunt L, Kaufman N, Champlin RE: Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 50:244, 1990.
9. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328:593, 1993.
10. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543, 1993.
11. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA, Gottschall JL, Oldham K, Anderson T, Camitta, B, Menitove J: Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 322:485, 1990.
12. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Anasetti C, Petersdorf EW, Mickelson EM, Pepe MS, Appelbaum FR, Buckne CD, Clift RA, Petersen FB, Stewart PS, Storb RF, Sullivan KM, Tesler MC, Witherspoon RP: Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 51:443, 1991.
13. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J Antibiot 40:1249, 1987.
14. Zeevi A, Eiras G, Bach FH, Fung JJ, Todo S, Starzl T, Duquesnoy RJ: Functional differentiation of human cytotoxic T lymphocytes in the presence of FK506 and CyA. Transplant Proc 22:106, 1990.
15. Kay JE, Moore AL, Doe SEA, Benzie CR, Schonbrunner R, Schmid FX, Halestrap AP: The mechanism of action of FK506. Transplant Proc 22:96, 1990.
16. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochia T: FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot 40:1256, 1987.
17. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A: FK506 for liver, kidney and pancreas transplantation. Lancet 2 (8670):1000, 1989.
18. Klintmalm GBG, Goldstein R, Gonwa T, Wiesner RH, Krom RAF, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, Busuttil RW, McDiarmid S, Esquivel CO, Nakazato P, Marsh JW, Woodle ES, Kalayoglu M, D'Alessandro AM, Pirsch JD, Miller C, Schwartz M, Lewis WD, Monaco AP, Jenkins RL, Emond JC, Thistlethwaite JR, Whitington PF, Steinmuller DR, Fitzsimmons WE, Lawrence I: Use of FK-506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. U.S. Multicenter FK506 Liver Study Group. Transplant Proc 25:635, 1993.
19. Jordan ML, Shapiro R, Vivas CA, Scantlebury VP, Darras FS, Carrieri G, McCauley J, Demetris AJ, Randhawa P, Jensen C, Hakala TR, Fung JJ, Starzl TE: FK506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 25:638, 1993.
20. The U.S. Multicenter FK56 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331:1110, 1994.
21. European FK506 Multicentre Liver Study Group: Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344:423, 1994.
22. Fay JW, Wingard JR, Antin JH, Collins RH, Piñeiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ: FK506 Monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 87:3514, 1996.
23. Fay JW, Collins RH, Piñeiro LA, Nemunaitis JJ, Aro R, Fitzsimmons W: FK506 to prevent graft-versus-host disease (GVHD) after allogeneic marrow transplantation (AMT) using unrelated marrow donors (UMD)-A phase II study. Blood 82:420a, 1993 (abstr).
24. American Society for Histocompatibility and Immunogenetics Laboratory Manual. 3rd Edition. ASHI. Lenexa, KS.
25. Park MS, Tonai R: Phenotype frequencies of the class II (DR, DQ) DNA alleles by the patterns of sequence-specific primer mixtures (SSPM) in four different populations and the probable haplotypes be ween DRB1 allele and DQB1 allele. Clinical Transplants 1992, Terasaki and Cecka, eds. UCLA Tissue Typing Laboratory, p 475.
26. Beatty PG: Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus. Blood 81:249, 1993.
27. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295, 1974.
28. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM: Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplantation 4:247, 1989.
29. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255, 1993.
30. Yau JC, Dimopoulos MA, Huan SD, Spencer V, Woo SY, Spitzer G, Brunner LJ, Wallerstein RO, Deisseroth AB, Andersson BS: An effective acute graft versus host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone. Am J Hematol 38:288, 1991.
31. Thyss A, Milano G, Renee N: Severe interaction between methotrexate and macrolide-like antibiotic. J Nat Cancer Instit 7:582, 1993 (letter).
32. Dix SP, Devine SM, Geller RB, Wingard JR: Lack of clinically significant interaction between low dose methotrexate and tacrolimus or cyclosporine in bone marrow transplant patients. J Natl Cancer Inst 87:1641, 1995.
33. De Groen PC, Aksamit AJ, Rakela J, Fortes GS, Krom RAF: Central nervous system toxicity after liver transplantation: The role of cyclosporine and cholesterol. N Engl J Med 1087:317:861.
34. Mueller AR, Platz KP, Bechstein WO, Schattenfroh N, Stoltenburg-Didinger G, Blumhardt G, Christe W, Neuhaus P: Neurotoxicity after orthotopic liver transplantation. Transplantation 58:155, 1994.
35. Wijdicks EFM, Wiesner RH, Dahlke LJ, Krom RAF: FK506-induced neurotoxicity in liver transplantation. Ann Neurol 35:498, 1994.
36. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986.
37. Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M, Appelbaum FR, Bensinger WI, Buckner CD, Clift RA, Doney K, Fefer A, McGuffin R, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP: Cyclosporine as prophylaxis for graft-versus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65:1325, 1985.
38. Storb R, Raff RF, Appelbaum Fr, Deeg HJ, Fitzsimmons W, Graham TC, Pepe M, Pettinger M, Sale G, van der Jagt R, Schuening FG: FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidenrical donors. Transplantation 56:800, 1993.
39. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, Sullivan K, van der Jagt R, Witherspoon R, Jusko WJ, Zager RA, Deeg HJ: Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood 85:3746, 1995.
40. Bacigalupo A, Maiolino A, Van Lint MT, Occhini D, Gualandi F, Clavio M, Lamparelli T, Tong J, Marmont AM: Cyclosporin A and chronic graft versus host disease. Bone Marrow Transplant 6:341, 1990.
41. Tuutu T, Volin L, Elonen E: Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids. Transplant Proc 20:491, 1988.